. Author manuscript; available in PMC: 2017 Apr 28.

Published in final edited form as: Br J Haematol. 2015 Dec 13;172(5):735–744. doi: 10.1111/bjh.13897

Table IV.

MYD88 and CXCR4 mutation status in patients with WM, IgM MGUS, MZL, CLL, MM and non-IgM MGUS patients.

	N	MYD88^L265P	CXCR4^WHIM
Healthy Donors	32	0 (0%)	0 (0%)
IgM MGUS	12	6 (50%)	2 (17%)
Non-IgM MGUS	7	0 (0%)	0 (0%)
Untreated WM	102	97 (95%)	44 (43%)
Treated WM	62	57 (92%)	21 (34%)
MZL	20	2 (10%)	1 (5%)
CLL	32	1 (3%)	0 (0%)
MM	14	0 (0%)	0 (0%)

WM, Waldenström Macroglobulinaemia; IgM, immunoglobulin M; MGUS, monoclonal gammopathy of unknown significance; MZL, marginal zone lymphoma; CLL, chronic lymphocytic leukaemia; MM, multiple myeloma: WHIM, Warts, Hypogammaglobulinemia, Infections and Myelokathexis; AS-PCR, allele-specific polymerase chain reaction.

CXCR4 mutation status includes all WHIM mutations identified by CXCR4^{S338X C>A} and ^C>G AS-PCR and Sanger sequencing.